CAPRICOR THERAPEUTICS, INC. 8-K
Clinical / regulatory decision
FDA extends Deramiocel review to assess new HOPE-3 data; Capricor seeks an indication focused on upper limb function.
Filed 2026-08-24 09:25 ET
- 8.01 Other Events
- 9.01 Financial Statements and Exhibits
Summary
FDA review extension for Deramiocel. The FDA moved the target action date for Capricor’s investigational Duchenne muscular dystrophy therapy after accepting a major amendment with 24-month HOPE-3 follow-up data and additional analyses. Capricor asked the FDA to consider a refined proposed indication focused on upper limb function, HOPE-3’s primary endpoint.
Key Figures
- PDUFA target action date: 11/22/2026, extended three months from 8/22/2026 to allow additional review of the amendment.
Investor Takeaways
- Watch for the FDA’s action by the new target date; the filing does not report an approval decision.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3